Mark Chadwick

Current

CEO at EnviroGene

Past

VP, Business Development at Excelsyn
VP, Development Services at Excelsyn
Director of Commercial Operations at BioFocus Discovery Ltd

Principal Scientist at BioFocus Discovery Ltd
Head of Molecular Biology at Cambridge Drug Discovery Ltd
Group Leader at Cambridge Genetics Ltd
Pfizer Senior Fellow, Gene Therapy at University of Cambridge, Corpus Christi College

see less...

4 more...

Education

Imperial College London
University of Cambridge
University of Newcastle-upon-Tyne

University of Nottingham

see less...

1 more...

Recommended

6 people have recommended Mark

Connections

349 connections

Industry

Environmental Services

Websites

My Company

Mark Chadwick’s Summary

Experienced in growing science and technology-based startup and turnaround companies.

Mark Chadwick’s Specialties:

Product deals, service deals, licensing deals, M&A, sales and marketing, business development, startup business

Mark Chadwick’s Experience

CEO

EnviroGene

(Environmental Services industry)

April 2009 — Present (4 months)

Leading a molecular diagnostics and source tracing biotech company. Envirogene offers services to trace the sources of pollution in waterways, reduce the clean-up costs of contaminated sites and enhance prediction efficiency when searching for sources of oil and gas.
VP, Business Development

Excelsyn

(Chemicals industry)

December 2007 — April 2009 (1 year 5 months)

Responsible for business development across Excelsyn. Turnover in excess of $28m in financial year 2007/8 (more than doubled since start of Excelsyn model - 3 years). Company moved into significant revenue generation from operations for the first time (>7% EBITDA/sales).
VP, Development Services

Excelsyn

(Privately Held; 51-200 employees; Pharmaceuticals industry)

May 2005 — December 2007 (2 years 8 months)

Running business unit focused on preclinical to phase II production of advanced intermediates and APIs. Grew headcount to 30. Grew customer base from scratch to over 60 and sales to ~$6m p/a.
Director of Commercial Operations

BioFocus Discovery Ltd

(Public Company; 51-200 employees; Pharmaceuticals industry)

2003 — 2005 (2 years)

Closed product, service and license deals in the US, Europe Japan and Australia. Business grew to >$30m and a 10% return on sales prior to acquisition by a Belgian biotech company (Galapagos) for $40m
Principal Scientist

BioFocus Discovery Ltd

(Public Company; 51-200 employees; GLPG; Pharmaceuticals industry)

2002 — 2003 (1 year)

Project management of drug discovery collaborations. Management of team of 12 scientists. Management and progression of IP portfolio
Head of Molecular Biology

Cambridge Drug Discovery Ltd

(Privately Held; 11-50 employees; Pharmaceuticals industry)

2000 — 2002 (2 years)

Led team of 8 scientists working on drug discovery projects
Group Leader

Cambridge Genetics Ltd

(Privately Held; 11-50 employees; Biotechnology industry)

1998 — 2000 (2 years)

Led team of 5 scientists working on a drug discovery exploitation route for a novel assay. Startup biotech company.
Pfizer Senior Fellow, Gene Therapy

University of Cambridge, Corpus Christi College

(Educational Institution; 1001-5000 employees; Research industry)

1995 — 1998 (3 years)

Post-doctoral research at the Laboratory of Molecular Biology (LMB). Technology was patented and became the platform for a biotechnology start-up company (CGL).

Mark Chadwick’s Education

Imperial College London

MBA with distinction , Entrepreneurship (distance learning) , 2002 — 2005

Supported by a Lord Sainsbury Management Fellowship award
University of Cambridge

Senior Fellowship , Gene Therapy , 1995 — 1998

Corpus Christi College
University of Newcastle-upon-Tyne

PhD , Molecular Biology , 1992 — 1995
University of Nottingham

BSc (Hons) 1st class , Genetics , 1989 — 1992